Across TCGA pan-cancer cohorts, IGLV2-23 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated IGLV2-23 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher IGLV2-23 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated IGLV2-23 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

UCEC, LSCC, and PDAC are the cancer types where IGLV2-23 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.810	1.000	.011	10	view →
LSCC	OS	Median	All	0.772	0.963	.003	9	view →
PDAC	DFS	Median	II,III,IV	0.493	0.299	.021	7	view →
GBM	DFS	Quartile	All	0.231	0.440	.042	4	view →
LUAD	OS	Median	III,IV	0.684	0.238	.048	2	view →
CCRCC	DFS	Quartile	All	0.891	0.525	.018	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

Exploration

Same gene, other analysis: IGLV2-23 tumor-vs-normal RNA expression · all IGLV2-23 data types